256 related articles for article (PubMed ID: 29743108)
1.
Schneider PM; Eshmuminov D; Rordorf T; Vetter D; Veit-Haibach P; Weber A; Bauerfeind P; Samaras P; Lehmann K
BMC Cancer; 2018 May; 18(1):548. PubMed ID: 29743108
[TBL] [Abstract][Full Text] [Related]
2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
[TBL] [Abstract][Full Text] [Related]
3.
Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
[TBL] [Abstract][Full Text] [Related]
4.
Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
[No Abstract] [Full Text] [Related]
5. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
[TBL] [Abstract][Full Text] [Related]
6. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
[TBL] [Abstract][Full Text] [Related]
8. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
[TBL] [Abstract][Full Text] [Related]
9. Early Assessment of Response to Neoadjuvant Chemotherapy with 18F-FDG-PET/CT in Patients with Advanced-Stage Ovarian Cancer.
Chung YS; Kim HS; Lee JY; Kang WJ; Nam EJ; Kim S; Kim SW; Kim YT
Cancer Res Treat; 2020 Oct; 52(4):1211-1218. PubMed ID: 32599990
[TBL] [Abstract][Full Text] [Related]
10. [
Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
[TBL] [Abstract][Full Text] [Related]
11. Fluorodeoxyglucose-positron emission tomography in adenocarcinomas of the distal esophagus and cardia.
Ott K; Weber WA; Fink U; Helmberger H; Becker K; Stein HJ; Müller J; Schwaiger M; Siewert JR
World J Surg; 2003 Sep; 27(9):1035-9. PubMed ID: 12917760
[TBL] [Abstract][Full Text] [Related]
12. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
Swisher SG; Maish M; Erasmus JJ; Correa AM; Ajani JA; Bresalier R; Komaki R; Macapinlac H; Munden RF; Putnam JB; Rice D; Smythe WR; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
Ann Thorac Surg; 2004 Oct; 78(4):1152-60; discussion 1152-60. PubMed ID: 15464463
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
[TBL] [Abstract][Full Text] [Related]
14. Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours.
Thomaschewski M; Hummel R; Petrova E; Knief J; Wellner UF; Keck T; Bausch D
World J Gastroenterol; 2018 Apr; 24(13):1429-1439. PubMed ID: 29632424
[TBL] [Abstract][Full Text] [Related]
15. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
17. 18F FDG-PET/CT evaluation of histological response after neoadjuvant treatment in patients with cancer of the esophagus or gastroesophageal junction.
Gabrielson S; Sanchez-Crespo A; Klevebro F; Axelsson R; Albert Tsai J; Johansson O; Nilsson M
Acta Radiol; 2019 May; 60(5):578-585. PubMed ID: 30111193
[TBL] [Abstract][Full Text] [Related]
18. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
[TBL] [Abstract][Full Text] [Related]
19. A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.
Smyth E; Schöder H; Strong VE; Capanu M; Kelsen DP; Coit DG; Shah MA
Cancer; 2012 Nov; 118(22):5481-8. PubMed ID: 22549558
[TBL] [Abstract][Full Text] [Related]
20. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
